Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Go back to Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1183.46 +1.57 (0.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1181.89 | 52 Week High | $88.16 | |||
| Open | $1185.32 | 52 Week Low | $67.88 | |||
| Day High | $1190.00 | P/E | 273.95 | |||
| Day Low | $1160.84 | EPS | $4.32 | |||
| Volume | 1,924,379 | |||||
